We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ranitidine bismuth citrate-based triple therapies as a second-line therapy forHelicobacter pyloriin Turkish patients.
- Authors
Köksal, Aydin Ş.; Parlak, Erkan; Filik, Levent; Yolcu, Ömer F.; Ödemiş, Bülent; Ülker, Aysel; Şaşmaz, Nurgurgül; Özden, Ali; Şahin, Burhan
- Abstract
Quadruple therapy with a proton pump inhibitor, bismuth, metronidazole and tetracycline is recommended as the optimal second-line therapy ofHelicobacter pyloriinfection in the Maastricht Consensus Report. The aim of the present paper was to evaluate the efficacy of ranitidine bismuth citrate (RBC)-based regimens as second-line therapies after failure of the standard Maastricht triple therapy.One hundred and sixteenH. pylori-positive patients were given omeprazole 20 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d for 10 days. Patients remainingH. pylori-positive (n = 29) were combined with 27 patients enrolled after an initial eradication failure from proton-pump inhibitor (PPI), amoxicillin and clarithromycin therapy for at least 7 days and were randomly given one of the following second-line 10-day treatments: RBC 400 mg b.d., amoxicillin 1 g b.d and clarithromycin 500 mg b.d. (RAC group,n = 28) and RBC 400 mg b.d., metronidazole 500 mg b.d and tetracycline 500 mg b.d. (RMT group,n = 28). Eradication was assessed by either histology and rapid urease test or13C urea breath test 8 weeks after therapy.The eradication rate of first-line Maastricht therapy was 67% for intention-to-treat analysis (95% confidence interval[CI]: 58–75). Per-protocol and intention-to-treat eradication was achieved in 60.7% of patients (95%CI: 42–79) in the RAC group and in 85.7% of patients (95%CI: 73–98) in the RMT group (P = 0.03). Fifty-three percent of patients in the RAC and 50% of patients in the RMT group experienced at least one slight side-effect (P = 0.6).RMT is an effective and well-tolerated second-line therapy afterH. pylorieradication failure from PPI, amoxicillin, and clarithromycin.
- Subjects
TURKEY; HELICOBACTER pylori infections; HELICOBACTER; THERAPEUTICS; RANITIDINE; ANTIHISTAMINES; PATIENTS
- Publication
Journal of Gastroenterology & Hepatology, 2005, Vol 20, Issue 4, p637
- ISSN
0815-9319
- Publication type
Article
- DOI
10.1111/j.1440-1746.2005.03801.x